Summary of Halozyme Therapeutics, Inc. (NASDAQ:HALO) Ratings as of May 17, 2018

May 17, 2018 - By Jack Shaw

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Corporate Logo
During Q4 2017 the big money sentiment increased to 1.66. That’s change of 0.40, from 2017Q3’s 1.26. 13 investors sold all, 45 reduced holdings as Halozyme Therapeutics, Inc. ratio is positive. 57 rose holdings while 39 funds took holdings. Funds hold 118.31 million shares thus 0.18% less from 2017Q3’s 118.53 million shares.
Nuveen Asset Mgmt Lc holds 0% or 23,846 shs in its capital. The Minnesota-based Us Natl Bank De has invested 0% in Halozyme Therapeutics, Inc. (NASDAQ:HALO). Morgan Stanley reported 0% stake. Ubs Asset Mgmt Americas has invested 0% in Halozyme Therapeutics, Inc. (NASDAQ:HALO). Alliancebernstein Limited Partnership has invested 0% of its capital in Halozyme Therapeutics, Inc. (NASDAQ:HALO). Wellington Group Llp reported 0% in Halozyme Therapeutics, Inc. (NASDAQ:HALO). Kennedy Management stated it has 507,978 shs or 0.18% of all its holdings. Third Security Ltd Liability Company holds 30.57% or 17.59 million shs in its capital. Art Advsrs Ltd Liability Corp stated it has 0.18% of its capital in Halozyme Therapeutics, Inc. (NASDAQ:HALO). Bb Biotech Ag accumulated 8.52M shs. The Maine-based Schroder Investment Management Grp has invested 0% in Halozyme Therapeutics, Inc. (NASDAQ:HALO). Advisory Service Net Ltd Liability Corporation reported 3,612 shs. Illinois-based Northern Trust Corporation has invested 0.01% in Halozyme Therapeutics, Inc. (NASDAQ:HALO). Senzar Asset Ltd Com has invested 2.78% of its capital in Halozyme Therapeutics, Inc. (NASDAQ:HALO). The Iowa-based Principal Gp has invested 0% in Halozyme Therapeutics, Inc. (NASDAQ:HALO).

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Ratings Coverage

In total 6 analysts cover Halozyme (NASDAQ:HALO). “Buy” rating has 3, “Sell” are 1, while 2 are “Hold”. (NASDAQ:HALO) has 50% bullish analysts. 9 are the (NASDAQ:HALO)’s ratings reports on May 17, 2018 according to StockzIntelligence Inc. On Wednesday, February 21 the stock of Halozyme Therapeutics, Inc. (NASDAQ:HALO) has “Buy” rating given by Canaccord Genuity. The company rating was maintained by Canaccord Genuity on Monday, May 14. On Wednesday, November 22 the rating was downgraded by Barclays Capital to “Hold”. On Thursday, February 22 the stock of Halozyme Therapeutics, Inc. (NASDAQ:HALO) has “Market Perform” rating given by BMO Capital Markets. The stock rating was downgraded by Barclays Capital to “Underweight” on Friday, May 11. The stock rating was maintained by JP Morgan with “Overweight” on Wednesday, February 21. On Wednesday, January 24 the company was maintained by Deutsche Bank. Listed here are Halozyme Therapeutics, Inc. (NASDAQ:HALO) PTs and latest ratings.

14/05/2018 Broker: Canaccord Genuity Rating: Buy New Target: $21.0000 Maintain
11/05/2018 Broker: Barclays Capital Old Rating: Equal-Weight New Rating: Underweight Old Target: $19 Downgrade
22/02/2018 Broker: BMO Capital Markets Old Rating: Market Perform New Rating: Market Perform Old Target: $18 New Target: $19 Maintain
21/02/2018 Broker: Canaccord Genuity Rating: Buy New Target: $21.0 Maintain
21/02/2018 Broker: JP Morgan Old Rating: Overweight New Rating: Overweight Old Target: $19 New Target: $22 Maintain
24/01/2018 Broker: Deutsche Bank Rating: Buy New Target: $21.0 Maintain
24/01/2018 Broker: Goldman Sachs Rating: Neutral New Target: $20 Initiates Coverage On
17/01/2018 Broker: BMO Capital Markets Rating: Hold New Target: $18.0
22/11/2017 Broker: Barclays Capital Rating: Hold New Target: $19.0 Downgrade

Ticker’s shares touched $18.16 during the last trading session after 2.47% change.Halozyme Therapeutics, Inc. has volume of 644,666 shares. Since May 17, 2017 HALO has risen 32.10% and is uptrending. The stock outperformed the S&P 500 by 20.55%.

Halozyme Therapeutics, Inc., a biotechnology company, researches, develops, and commercializes human enzymes and other drug candidates in the United States, Switzerland, and internationally.The firm is worth $2.60 billion. The companyÂ’s human enzymes are used to facilitate the delivery of injected drugs and fluids, enhancing the efficacy and the convenience of other drugs or can be used to alter tissue structures for clinical benefit.The P/E ratio is 40.36. The Company’s products are based on the Enhanze technology, a patented recombinant human hyaluronidase enzyme that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.

More recent Halozyme Therapeutics, Inc. (NASDAQ:HALO) news were brought out by Benzinga.com, Seekingalpha.com and Benzinga.com. The first one has “22 Stocks Moving In Friday’s Pre-Market Session” as a title and was brought out on May 11, 2018. The next is “Premarket analyst action – healthcare” on May 11, 2018. And last was brought out on May 11, 2018, called “38 Stocks Moving In Friday’s Mid-Day Session”.

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Institutional Investors Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.